This review examines pharmacokinetics of CAR T cell therapy in multiple myeloma, highlighting its implications for treatment efficacy.
More than a decade after the initial clinical reports of chimeric antigen receptor (CAR) T-cell therapy emerging from early-phase trials and individual case studies [ 1 , 2 , 3 ]. CAR T cells directed against B-cell maturation antigen (BCMA) have now evolved into an established standard of care for patients with relapsed or refractory multiple myeloma (RRMM) [ 4 ].
No takes yet. Share an insight, caveat, or question.
Merz et al. (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: